Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

812 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis.
Wenger AL, Barakovic M, Bosticardo S, Schaedelin S, Daducci A, Schiavi S, Weigel M, Rahmanzadeh R, Lu PJ, Cagol A, Kappos L, Kuhle J, Calabrese P, Granziera C. Wenger AL, et al. Among authors: kappos l. Front Neurosci. 2023 Feb 7;17:1007580. doi: 10.3389/fnins.2023.1007580. eCollection 2023. Front Neurosci. 2023. PMID: 36824214 Free PMC article.
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Kappos L, et al. Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Lancet. 2008. PMID: 18970976 Clinical Trial.
Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
Callegari I, Oechtering J, Schneider M, Perriot S, Mathias A, Voortman MM, Cagol A, Lanner U, Diebold M, Holdermann S, Kreiner V, Becher B, Granziera C, Junker A, Du Pasquier R, Khalil M, Kuhle J, Kappos L, Sanderson NSR, Derfuss T. Callegari I, et al. Among authors: kappos l. Brain. 2024 Mar 1;147(3):839-848. doi: 10.1093/brain/awad424. Brain. 2024. PMID: 38123517 Free PMC article.
A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients.
Todea AR, Melie-Garcia L, Barakovic M, Cagol A, Rahmanzadeh R, Galbusera R, Lu PJ, Weigel M, Ruberte E, Radue EW, Schaedelin S, Benkert P, Oezguer Y, Sinnecker T, Müller S, Achtnichts L, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Lalive P, Bridel C, Zecca C, Derfuss T, Remonda L, Wagner F, Vargas M, Du Pasquier R, Pravata E, Weber J, Gobbi C, Leppert D, Wuerfel J, Kober T, Marechal B, Corredor-Jerez R, Psychogios M, Lieb J, Kappos L, Cuadra MB, Kuhle J, Granziera C; Swiss MS Cohort Study. Todea AR, et al. Among authors: kappos l. J Magn Reson Imaging. 2023 Sep;58(3):864-876. doi: 10.1002/jmri.28618. Epub 2023 Jan 28. J Magn Reson Imaging. 2023. PMID: 36708267 Free article.
Postmortem quantitative MRI disentangles histological lesion types in multiple sclerosis.
Galbusera R, Bahn E, Weigel M, Schaedelin S, Franz J, Lu PJ, Barakovic M, Melie-Garcia L, Dechent P, Lutti A, Sati P, Reich DS, Nair G, Brück W, Kappos L, Stadelmann C, Granziera C. Galbusera R, et al. Among authors: kappos l. Brain Pathol. 2023 Nov;33(6):e13136. doi: 10.1111/bpa.13136. Epub 2022 Dec 8. Brain Pathol. 2023. PMID: 36480267 Free PMC article.
Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus.
Papadopoulou A, Pfister A, Tsagkas C, Gaetano L, Sellathurai S, D'Souza M, Cerdá-Fuertes N, Gugleta K, Descoteaux M, Chakravarty MM, Fuhr P, Kappos L, Granziera C, Magon S, Sprenger T, Hardmeier M. Papadopoulou A, et al. Among authors: kappos l. Clin Neurophysiol. 2024 May;161:122-132. doi: 10.1016/j.clinph.2024.02.020. Epub 2024 Feb 20. Clin Neurophysiol. 2024. PMID: 38461596 Free article.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Montalban X, et al. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. N Engl J Med. 2019. PMID: 31075187 Clinical Trial.
812 results